ANIK Anika Therapeutics Inc.

Anika to Participate in the Sidoti Virtual Investor Conference

Anika to Participate in the Sidoti Virtual Investor Conference

BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET.

Webcast of the presentation and Q&A will be available in the  section of Anika’s website, . An archive of the presentation will also be available on the website.

About Anika

 (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid (“HA”) innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis (“OA”) pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit 

ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

For Investor Inquiries:

Anika Therapeutics, Inc.

Matt Hall, 781-457-9554

Director, Corporate Development and Investor Relations



EN
07/05/2025

Underlying

ANIKAnika Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

Anika Reports Fourth Quarter and Full Year 2025 Financial Results Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain manag...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Confere...

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the under the Investors section of Anika Therapeuti...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on T...

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (internat...

February 12, 2026 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Therapeutics Announces Leadership Transition

Anika Therapeutics Announces Leadership Transition Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chie...

January 8, 2026 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Third Quarter 2025 Financial Results

Anika Reports Third Quarter 2025 Financial Results Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the ...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch